LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

EDAN Takes its Solutions up a Notch at MEDICA 2022

By LabMedica International staff writers
Posted on 16 Nov 2022
Image: EDAN at MEDICA 2022 with its latest innovations (Photo courtesy of EDAN)
Image: EDAN at MEDICA 2022 with its latest innovations (Photo courtesy of EDAN)

EDAN Instruments, Inc. (Shenzhen, China) is demonstrating its range of latest innovations at MEDICA, the premiere global medical trade show being held at Dusseldorf, Germany, from Nov. 14 to 17, 2022. The company is presenting five new products to more than 120,000 visitors from over 150 countries at the world’s largest trade fair for the medical sector.

For the laboratory sector, EDAN is showcasing its combined range of POCT and IVD innovations at its booth this year, including the ClariLight CL30, its first molecular diagnostics solution. The ClariLight CL30 is a new point of care (POC) molecular diagnostics analysis system based on Loop-Mediated Isothermal Amplification (LAMP) that provides on-the-spot results and empowers physicians for early infectious disease diagnostics, thanks to its agility, speed and flexibility. ClariLight CL30 is designed to offer effective solutions for infectious disease diagnostics by reducing the window period. Unlike PCR-based methods (generally non-portable, laboratory setting, time-consuming), CL30 produces molecular results as quick as 15 minutes, while multi-parameters cartridges and the extraction-free procedure allow massive and rapid molecular tests feasible.

At MEDICA 2022, EDAN is also showcasing iX Series, its next-generation patient monitor that comes with a widescreen design and optimized workflow. Its innovative non-invasive technologies and selective clinical tools contribute to more efficient patient monitoring. Visitors to EDAN’s booth at MEDICA 2022 can experience two ready-to-launch products from the company, including the fully-automated electrocardiograph SE-1201 Pro, and the Holter ECG & ABP 2-in-1 wearables SA-20, tailored for the diagnosis of cardiogenic hypertension. In the obstetrics & gynecology area, EDAN is presenting its portable biofeedback and stimulation system, PA4 Pro, which allows physiotherapists to deliver pelvic floor muscular assessment and treatment flexibly in any scenario. For the first time, EDAN is also exhibiting the upgraded version of Acclarix LX9 alongside its technologically upgraded transducers.

"The highlight is our first molecular diagnostics solution, ClariLight CL30. We are glad to see that most clients are attracted by its rapid results as quick as 15 minutes," said Bo Wang, IVD & POCT Marketing Manager at EDAN.

"A rolling stone gathers no moss. Our breakthrough is visible," said Alex You, Senior Director of EDAN Global Marketing & Strategic Operations, after having a dialogue on EDAN's global development plan with Mr. Wolfram Nikolaus Diener, President & CEO of Messe Dusseldorf GmbH. "And we will go further with a steady stream to advance in our journey towards improving human living conditions."

Related Links:
EDAN Instruments, Inc.

Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
CBM Analyzer
Complete Blood Morphology (CBM) Analyzer

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more